NASDAQ: BRNSBarinthus Biotherapeutics PLC Stock
$1.03+0.00 (+0%)
Updated Mar 25, 2025
BRNS Price
$1.03
Fair Value Price
N/A
Market Cap
$41.35M
52 Week Low
$0.80
52 Week High
$4.16
P/E
-0.66x
P/B
0.32x
P/S
3.18x
PEG
N/A
Dividend Yield
N/A
Revenue
$14.97M
Earnings
-$61.07M
Gross Margin
100%
Operating Margin
-407.94%
Profit Margin
-408%
Debt to Equity
0.23
Operating Cash Flow
-$29M
Beta
0.89
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
BRNS Overview
Vaccitech Public Limited Company is a biopharmaceutical company developing T-cell immunotherapeutics and vaccines for the treatment of infectious diseases and cancers. The company's pipeline includes VTP-300, in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection, VTP-200, in Phase 1/2a clinical trial for the treatment of human papilloma virus infection, and VTP-850, in Phase 1/2 clinical trial for the treatment of prostate cancer. Vaccitech was founded in 2016 and is headquartered in Oxford, UK.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BRNS's potential to beat the market
- BRNS doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
BRNS
RankedUnranked of 481
RankedUnranked of 481
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.53 | A | |
| $135.25 | A | |
| $7.52 | A |
Be the first to know about important BRNS news, forecast changes, insider trades & much more!
BRNS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BRNS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BRNS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BRNS is good value based on its book value relative to its share price (0.32x), compared to the US Biotechnology industry average (4.62x)
P/B vs Industry Valuation
BRNS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BRNS due diligence checks available for Premium users.
Valuation
BRNS fair value
Fair Value of BRNS stock based on Discounted Cash Flow (DCF)
Price
$1.03
Fair Value
$3.20
Undervalued by
67.85%
BRNS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BRNS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.66x
Industry
-116.9x
Market
32.24x
BRNS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.32x
Industry
4.62x
BRNS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BRNS's financial health
Profit margin
Revenue
$0.0
Net Income
-$20.5M
Profit Margin
0%
BRNS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
BRNS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$160.3M
Liabilities
$30.2M
Debt to equity
0.23
BRNS's short-term assets ($125.74M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BRNS's short-term assets ($125.74M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BRNS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BRNS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$13.1M
Investing
-$278.0k
Financing
$837.0k
BRNS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BRNS vs Biotech Stocks
Barinthus Biotherapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.